- Oral anti-pseudomonal antibiotics for cystic fibrosis (Link updated Jan. 20, 2008)
- This comes in both a preservative-free form, and also with preservatives. Generally, it is better to inhale the one without preservatives, because the one with preservatives will often cause some bronchoconstriction and other side-effects. (Added Jan. 20, 2008)
- Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis (Link updated Oct. 22, 2002)
- Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection (Link updated Jan. 20, 2008)
- Eradication of Initial Pseudomonas aeruginosa Colonization in Patients with Cystic Fibrosis (Added Mar. 18, 2002)
- Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis (Added Mar. 9, 2003)
- Evaluation of Bronchial Constriction in Children With Cystic Fibrosis After Inhaling Two Different Preparations of Tobramycin (Added Mar. 19, 2003)
- Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis (Link updated Jan. 20, 2008)
- Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report (Added Mar. 6, 2007)
- TOBI by Novartis (Added Oct. 10, 2007)
- TOBI Patient Assistance Program Provides assistance to patients experiencing financial hardship who have no third-party insurance coverage for their medicine (Link updated Jan. 20, 2008)
- TOBI Can Save Money For Canadian CF Patients (Added June 14, 1999)
- PathoGenesis Corp. Announces Two-Year Data on TOBI (Added June 15, 1999)
- Evaluation of Bronchial Constriction in Children With Cystic Fibrosis After Inhaling Two Different Preparations of Tobramycin (Added Mar. 19, 2003)
- Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease (Added Sept. 14, 2004)
- Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis (Link updated Jan. 20, 2008)
- Highly effective antibiotic used widely in Europe.
- After a while, in some people, using it alone has caused some new sensitivity to certain other drugs that they were once resistant to.
- Aerosolized colistin sodium may be a useful therapy to promote emergence of sensitive microbes in CF candidates with pan-resistant isolates of Pseudomonas (PA).
- No bad smell or taste; the taste for a second is like butterscotch.
- PA does not appear to become resistant to this class of antibiotics. (Added Dec. 2, 1998)
- Foams when being mixed. When reconstituting the mixture, inject the sterile water into the powder slowly. It might be better to use sterile water that has been refrigerated beforehand. Then gently roll the bottle between both hands. Do not shake vigorously. Check the bottle to make sure the powder is completely dissolved. Let the bottle sit for a while, to let the foam settle, before nebulizing. (Info updated Jan. 20, 2008)
- Some people may experience bronchoconstriction with this med. Using a brochodilating med just prior may help (either by inhaler or by nebulization).
- The clinical use of colistin in patients with cystic fibrosis (Link updated Jan. 20, 2008)
- The pharmacokinetics of colistin in patients with cystic fibrosis (Link updated Aug. 26, 2005)
- Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis (Added Feb. 15, 2005)
- Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis (Link updated Jan. 20, 2008)
- Foundation Issues a Safety Alert Regarding Premixed Inhaled Colistin on June 12, 2007 The Cystic Fibrosis Foundation recommends that patients not use inhaled colistin that has been premixed by a pharmacy until the FDA investigation is complete and the safety of this product is established. (Link updated Sept. 29, 2009)
- FDA Safety Alert June 2007 Once Colistimethate is mixed into a liquid form, the product breaks down into other chemicals that can damage lung tissue. Healthcare professionals who choose to prescribe Colistimethate to treat patients with CF should be aware of the potential for serious and life threatening side effects from inhalation of pre-mixed, ready-to-use liquid forms of the product. Patients should discard any unused pre-mixed liquid forms of Colistimethate. (Link updated Sept. 29, 2009)
- Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis (Added Mar. 31, 2008)
- Less commonly used for inhalation.
- Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis (Link updated Jan. 20, 2008)
- Not commonly used for inhalation. Fairly frequently used via the IV route.
- Rarely used for inhalation, usually given IV.
- Aerosolized Vancomycin therapy facilitating nursing home placement (Added Sept. 17, 2000)
- Corus Pharma Receives Orphan Drug Designation for Aztreonam For Inhalation Therapy (Added Mar. 21, 2002)
- Expanded Access Program for CF Intended to give eligible Cystic Fibrosis patients with Pseudomonas aeruginosa and limited or no treatment options access to the investigational formulation of aztreonam lysinate for inhalation. (Link and info updated Jan. 20, 2008)
- Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis (Added Sept. 19, 2006)
- Gilead Submits New Drug Application to U.S. FDA for Aztreonam Lysine for Inhalation for Cystic Fibrosis (Added Mar. 19, 2008)
- European Commission Grants
Conditional Marketing Authorization to Cayston(R) (Aztreonam Lysine) for the
Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in
Patients with Cystic Fibrosis
(Added Sept. 27,
2009)
- Novel Form of Ciprofloxacin to Treat Cystic Fibrosis Lung Infections (Link updated Feb. 24, 2006)
- MP-376 (Levofloxacin Solution for Inhalation) Clinical Program for Cystic Fibrosis (CF) (Added Mar. 19, 2008)
- Mpex Pharmaceuticals Initiates Multi-dose Clinical Trial in the U.S. with MP-376 in Patients with Cystic Fibrosis (Added Mar. 19, 2008)
- Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis Phase 2b Trial Expected to Begin in the Second Quarter of 2008 (Added Mar. 19, 2008)